Quince Q2 FY26 net loss widens to $75.5 million
Reuters2026/08/14 12:00- Quince Therapeutics posted a GAAP net loss of USD 75.5 million, or USD 12.31 per share, for Q2 2026.
- R&D expense fell 16.67% to USD 5.5 million; the decline reflected lower eDSP program costs, partly offset by higher LAM-001 startup spending.
- G&A expense more than doubled to USD 16.6 million, driven by a USD 9.1 million non-cash stock-comp charge and higher professional fees.
- Cash and cash equivalents totaled USD 116 million at June 30, 2026, following USD 103.6 million in net upfront private placement proceeds.
- LAM-001 Phase 2 BOS data is expected in Q1 2027; Phase 2b PH-ILD data is expected in Q1 2028, with a SAPH Phase 2 start planned late 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Colgate-Palmolive (CL.US) plans to sell part of its personal care brands, with a total transaction amount possibly exceeding 1.1 billions USD.
According to sources familiar with the matter, Colgate is exploring the sale of some of its mass-market personal care brands. The company currently plans to divest only a few brands within its personal care business, and the combined sale price may exceed 1 billion dollars.
EdiliziAcrobatica announces shareholder meeting notice
Storage Giant Offers Huge Bonuses Again: Micron Awards Up to 68 Months’ Bonus
Micron Technology has announced record-breaking bonuses for its employees in Taiwan, ranging from 35 to 68 months’ salary, with a minimum cash compensation of 1.7 million New Taiwan dollars. However, the Taoyuan union, representing about two-thirds of Micron’s workers in Taiwan, has refused to accept the offer, insisting that 15% of operating profits be included in the bonus distribution and maintaining the threat of a strike.
Crypto prices
More
